Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00147368
Status:
COMPLETED
Last Update Posted:
2008-06-02
First Post:
2005-09-06
Brief Title:
Arginine Malaria Trial Study of Adjunctive Arginine in Falciparum Malaria
Sponsor:
Menzies School of Health Research
Organization:
Menzies School of Health Research
Study Overview
Official Title:
Pharmacokinetic-Pharmacodynamic Study of Adjunctive Arginine in Falciparum Malaria
Status:
COMPLETED
Status Verified Date:
2008-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Acute falciparum malaria is associated with low plasma arginine and impaired nitric oxide NO production Both are associated with poor outcome This study will examine the safety and effect of escalating doses of arginine in falciparum malaria It will determine whether arginine can increase NO production and have an effect on NO-dependent physiological measurements The hypothesis is that arginine will be safe in falciparum malaria will return plasma arginine concentration to normalsupranormal levels will increase systemic and exhaled NO reduces oxidant stress and improves a number of NO-dependent physiological measures of relevance to malaria
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| GR071614MA - Wellcome Trust | None | None | None |